No Data
No Data
Biogen's Strategic Acquisitions and Growth Potential: An Analyst's Hold Rating Justification
Goldman Sachs Adjusts Price Target on Biogen to $342 From $340, Maintains Buy Rating
Biogen (BIIB) has an average outperform rating and a price target range of $200 to $350, according to analysts polled by Capital IQ.Price: 222.01, Change: +0.43, Percent Change: +0.19
Jeito Capital Consolidates Its Support in CatalYm With a Renewed Participation in a $150 Million Financing
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial burden it places on patients.
Lexeo Stock Drops 24% Amid Friedreich Ataxia Study Results
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A